Differences

This shows you the differences between two versions of the page.

--- acr2026 [2026/09/21 12:39] – admin
+++ acr2026 [2026/09/30 19:52] (current) – admin
@@ Line 1: / Line 1: @@
-**Poster presenter (name, credentials, title, institution)**
+====== Admin Details ======
-Eric W. Robbins, MD
+{{ :itinerary_pwzf4p_28sep_robbins.pdf |itinerary}}
-Clinical Fellow
+^ place                                    ^ Map ^ Address ^ Phone^
+| Hotel                                | [[ https://maps.app.goo.gl/YD9W4zZMc1fFaBEU9| Hilton Chicago]] | 720 S Michigan Ave, Chicago, IL 60605| 312-922-4400|
+| Conference Venue|[[https://maps.app.goo.gl/waGyp1qzgnBwcURt5 | McCormick Place]]|2301 S Martin Luther King Dr, Chicago, IL 60616|312-791-7000|
-Critical Care Medicine and Pulmonary Branch; National Heart, Lung, and Blood Institute
+^Origin ^ Destination ^ Flight ID^
+| DCA |ORD |AA 1165|
+| ORD | DCA| AA 2249|
-National Institutes of Health
+====== Transit ======
-**Poster title:**
+App: [[https://www.ventrachicago.com/ | Ventra]]
-Serial Quantitative Changes in Anti-Scl-70 Autoantibodies Are Associated with Lung Function Decline in Systemic Sclerosis
+<todo>At O'Hare, purchase a 3-day disposable Ventra pass</todo>
-**What is your poster about?**
+=== From Airport to Hotel ===
-Our study investigates whether dynamic, quantitative monitoring of anti-Scl-70 autoantibody titers can predict lung function decline and disease progression in patients with systemic sclerosis (SSc). Using a research assay known as luciferase immunoprecipitation systems (LIPS), we evaluated patients from the multicenter CONQUER registry. We found that certain early dynamic changes in quantitative anti-Scl-70 levels
+CTA Blue line from _O'Hare_ to _Jackson_
+=== From Hotel to Venue ===
-were associated with subsequent forced vital capacity (FVC) decline. Specifically, a >30% early increase in anti-Scl-70 levels was associated with a nearly four-fold increased risk of pulmonary progression over two years.
+  * Option 1:
+    * [[https://maps.app.goo.gl/7ToNXXqLJGKFngcN6 | Take bus 3 from directly in front of hotel to venue]]
+  * Option 2:
+    * [[https://maps.app.goo.gl/w5rKjyFAurhTronY8 | Walk to Museum Campus / 11th street stop and take Orange line]]
-**Why did you decide to investigate this topic?**
-Our group had previously done work in myositis-associated interstitial lung disease (ILD), and we wanted to broaden our focus to other rheumatic disease resulting in pulmonary fibrosis.
+====== Schedule ======
-We knew that anti-Scl-70 autoantibodies are a well-established risk factor for systemic sclerosis–associated ILD, but we wanted to see if there was a more dynamic measure we could follow that might tell clinicians a patient's risk trajectory.
-Our hope was to find a measure clinicians could serially monitor to better predict a patient's risk of pulmonary worsening.
-**What are you working on next related to this research?**
+  * Sun, Oct 26
+    * 09:59 flight, DCA to ORD
-Broadly, we are working on a new project to investigate shared proteomic profiles of pulmonary fibrosis across a spectrum of autoimmune rheumatic diseases, such as myositis, systemic sclerosis, and Sjögren's syndrome.
+    * 11:06 arrival in ORD
+  * Mon, Oct 27
-Simultaneously, to directly extend the specific work in this abstract, we plan to implement high-breadth proteomic profiling in the CONQUER cohort.
+    * 10:30 - 12:30, Marce poster
-We anticipate this expanded analyte coverage will provide deeper biological insights and identify stronger molecular correlations with the risk of pulmonary progression.
+      * Hall F1
+  * Tue, Oct 28
-We're currently working on a project looking at shared proteomic profiles of pulmonary fibrosis across a number of rheumatic diseases (myositis, systemic sclerosis, Sjögren's, etc.).
+    * 10:30 - 12:30, My abstract
-To extend the work in this abstract, we think that incorporating high-breadth proteomic profiling.
+      * Hall F1, 1949
-That approach will allow us to capture a more comprehensive biological narrative and hopefully uncover molecular signatures tightly correlated with clinical progression.
+    * 17:19 flight, ORD to DCA
+    * 20:16 arrival in DCA
-**What excites you most about your work?**
-I'm excited about the possibility of having more tools to enable dynamic, proactive monitoring in scleroderma ILD care, rather than just a static risk assessment.
-Identifying an early biomarker trajectory that precedes clinical decline could give rheumatologists and pulmonlogits a crucial window of opportunity to tailor their monitoring or therapeutic strategies before irreversible lung damage occurs.
-**What are you most looking forward to at ACR Convergence 2026 in Orlando?**
-As a pulmonologist, I look forward to connecting with rheumatology colleagues, translational researchers, and other ILD specialists.
-There's some amazing work going on in the rheumatic biomarker field, and I'm keenly watching several ongoing trails testing new immunotherapies in refractory rheumatologic disease.
-I am eager to share these insights from the CONQUER cohort, see what other findings presented might be integrated into clinical workflows, and discover new advancements across the field of rheumatology.
-  * <del>[[https://rheumatology.org/annual-meeting-abstract-submission | ACR 2026, abstract submission]]</del>
-=== Registration ===
-Early Registration: August 26, 23:59 EST
-Timing: November 6–11
-=== Abstract Character Limit ===
-  * Title limit: 250 characters, excluding spaces
-  * Body character limit: 2,750 characters, which EXCLUDES the title, names of authors/co-
-authors, authors' affiliations, spacing, and disclosures.
-  * limit of three image, table, and/or graphic uploads per submission. Uploaded tables and/or graphics do not count towards the character limit.
-  * References in the abstract body will be included in the character count.
-[[https://www.clinexprheumatol.org/acronyms.asp | acceptable abbreviations]]

ewrobbins.com

User Tools

Site Tools

Differences

Page Tools